Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

Market Cap	3.61B +4.7%
Revenue (ttm)	543.82M -19.3%
Net Income	-240.38M
EPS	-1.83
Shares Out	130.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,432,987
Open	24.26
Previous Close	26.78
Day's Range	24.26 - 28.65
52-Week Range	22.58 - 61.76
Beta	-0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About SHE:300683

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 958
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300683

Financial Performance

In 2025, SHE:300683's revenue was 541.45 million, a decrease of -16.57% compared to the previous year's 648.97 million. Losses were -231.27 million, 233.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error